Search
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Pancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigationalPancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.
Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,Nickel sulfate
go.drugbank.com/drugs/DB14180ApprovedNickel sulfate is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingSynonyms: nickel(II) sulfateLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Lactulose
go.drugbank.com/drugs/DB00581ApprovedInvestigationalOrganization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system[L6205], data regarding its optimal place in therapy is often ambiguous. … Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within
Mirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food. … Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body.